The estimated Net Worth of Phillip P. Chan is at least $2.47 Milion dollars as of 13 December 2023. Mr. Chan owns over 75,188 units of Cytosorbents Corp stock worth over $1,068,704 and over the last 15 years he sold CTSO stock worth over $0. In addition, he makes $1,404,380 as President, Chief Executive Officer a Director at Cytosorbents Corp.
Phillip has made over 20 trades of the Cytosorbents Corp stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 75,188 units of CTSO stock worth $100,000 on 13 December 2023.
The largest trade he's ever made was buying 190,000 units of Cytosorbents Corp stock on 4 September 2012 worth over $24,700. On average, Phillip trades about 15,354 units every 98 days since 2010. As of 13 December 2023 he still owns at least 1,068,704 units of Cytosorbents Corp stock.
You can see the complete history of Mr. Chan stock trades at the bottom of the page.
Phillip P. Chan M.D. Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Chan became a director of the Company in 2008, and since January 2009 has served as President and Chief Executive Officer. Prior to joining CytoSorbents, Dr. Chan led healthcare and life science investments for the NJTC Venture Fund from 2003 to 2008, most recently as a Partner. In 2006, Dr. Chan co-founded Andrew Technologies, a medical device company commercializing its FDA-approved HydraSolve TM lipoplasty system for plastic surgery. He is an Internal Medicine physician with a strong background in clinical medicine and research. Dr. Chan received his MD and PhD from the Yale University School of Medicine, completed his Internal Medicine residency at the Beth Israel Deaconess Medical Center at Harvard Medical School, and received his Board certification. He also holds a BS in cell and molecular biology from Cornell University.
As the President, Chief Executive Officer a Director of Cytosorbents Corp, the total compensation of Phillip Chan at Cytosorbents Corp is $1,404,380. There are no executives at Cytosorbents Corp getting paid more.
Phillip Chan is 49, he's been the President, Chief Executive Officer a Director of Cytosorbents Corp since 2009. There are 11 older and no younger executives at Cytosorbents Corp. The oldest executive at Cytosorbents Corp is Dr. Robert H. Bartlett, 82, who is the Co-Chairman of Cardiac Surgery Advisory Board & Consultant.
Phillip's mailing address filed with the SEC is C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON, NJ, 08540.
Over the last 16 years, insiders at Cytosorbents Corp have traded over $1,216,453 worth of Cytosorbents Corp stock and bought 832,447 units worth $1,058,402 . The most active insiders traders include James T. Gunton, Al Kraus a Phillip P. Chan. On average, Cytosorbents Corp executives and independent directors trade stock every 34 days with the average trade being worth of $41,883. The most recent stock trade was executed by Alan D. Sobel on 13 December 2023, trading 22,557 units of CTSO stock currently worth $30,001.
cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents' purification technologies are based on biocompatible, highly porous polymer beads
Cytosorbents Corp executives and other stock owners filed with the SEC include: